Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by diadon1945on Feb 20, 2008 12:50pm
160 Views
Post# 14400286

The International Stroke Conf. begins today

The International Stroke Conf. begins todayThat means international coverage of the presentation to the Conference...international interest in Tuesdays webcast..and some international buying. It will be interesting to see more details....the big thing is that there is both safety and efficacy. That is what potential partners are looking for. We know there is international interest as the CEO spoke to Japanese and Korean companies last year...and no doubt they are following this treatment with interest as there is a huge stroke rate in their countries....and few if any alternatives!
Bullboard Posts